Fresenius Medical Care (FMS) Expected to Announce Quarterly Earnings on Tuesday

Fresenius Medical Care (NYSE:FMS) is expected to issue its quarterly earnings data before the market opens on Tuesday, February 18th. Analysts expect the company to announce earnings of $0.41 per share and revenue of $5.65 billion for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Fresenius Medical Care Stock Performance

NYSE:FMS opened at $24.18 on Tuesday. The company has a market cap of $14.19 billion, a price-to-earnings ratio of 19.98, a PEG ratio of 0.80 and a beta of 0.93. Fresenius Medical Care has a 1 year low of $17.93 and a 1 year high of $25.25. The stock’s 50 day simple moving average is $23.41 and its two-hundred day simple moving average is $21.40. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on FMS shares. StockNews.com upgraded shares of Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Truist Financial upped their price objective on Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a research report on Monday, January 6th. Finally, Berenberg Bank started coverage on Fresenius Medical Care in a report on Wednesday, November 6th. They issued a “buy” rating and a $25.60 target price for the company.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.